Angelini Tachipirina Early Childhood 125mg Paracetamol 10 Suppositories

Product details

Therapeutic indications
Tachipirina 125 Early Childhood Suppositories can be used:

As antipyretic: symptomatic treatment of febrile diseases such as flu, exanthematous diseases, acute respiratory tract diseases, etc.
As an analgesic: headaches, neuralgia, myalgia and other painful manifestations of medium entity, of various origins

Dosage and method of use
For children it is essential to respect the dosage defined according to their body weight, and therefore to choose the suitable formulation. Approximate ages as a function of body weight are given for information only. Below three months, in case of jaundice, it is advisable to reduce the single oral dose.

In adults, the maximum oral dose is 3000 mg and rectally 4000 mg of paracetamol per day. The physician should assess the need for treatment for more than 3 consecutive days. The dosage schedule of Tachipirina in relation to body weight and route of administration is as follows

Children weighing between 6 and 7 kg (approximately between 3 and 6 months): 1 suppository at a time, to be repeated if necessary after 6 hours, without exceeding 4 doses per day.
Children weighing between 7 and 10 kg (approximately between 6 and 18 months): 1 suppository at a time, to be repeated if necessary after 4 - 6 hours, without exceeding 5 doses per day.
Children weighing between 11 and 12 kg (approximately between 18 and 24 months): 1 suppository at a time, to be repeated if necessary after 4 hours, without exceeding 6 doses per day.

Contraindications

Hypersensitivity to the active substance, or to any of the excipients
Patients with severe haemolytic anemia (this contraindication does not refer to the 500mg oral formulations)
Severe hepatocellular insufficiency (this contraindication does not refer to oral formulations of 500mg).

Special warnings
In rare cases of allergic reactions, administration should be discontinued and appropriate treatment instituted. Use with caution in case of chronic alcoholism, excessive alcohol intake (3 or more alcoholic drinks per day), anorexia, bulimia or cachexia, chronic malnutrition (low reserves of hepatic glutathione), dehydration, hypovolemia.

Paracetamol should be administered with caution to patients with mild to moderate hepatocellular insufficiency (including Gilbert's syndrome), severe hepatic insufficiency (Child-Pugh> 9), acute hepatitis, concomitant treatment with drugs that impair liver function, deficiency of glucose-6-phosphate dehydrogenase, haemolytic anemia. High or prolonged doses of the product can cause alterations in the kidney and blood, even serious, therefore the administration in subjects with renal insufficiency must be carried out only if actually necessary and under direct medical supervision. In case of prolonged use it is advisable to monitor liver and kidney function and blood count.

During treatment with paracetamol, before taking any other drug, check that it does not contain the same active ingredient, as serious adverse reactions can occur if paracetamol is taken in high doses. Instruct the patient to contact the physician before associating any other medication.

Pregnancy and breastfeeding
Although clinical studies in pregnant or lactating patients have not shown particular contraindications to the use of paracetamol or caused unwanted effects affecting the mother or child, it is recommended to administer the product only in cases of real need and under the direct supervision of the doctor. .

Expiration and retention
Check the expiration date indicated on the package. The expiry date indicated refers to the product in intact packaging, correctly stored

Warning: do not use the medicine after the expiry date indicated on the package.

Composition
Tachipirina 125 Early Childhood Suppositories contains:
Active ingredient: paracetamol 125 mg
Excipients: solid semisynthetic glycerides.

This sheet has been prepared using information provided by the manufacturer. It should be noted that the packaging of the products is susceptible to periodic renewals by the pharmaceutical companies, therefore the photo of the product may not be updated; the only data to be trusted is the unique ministerial code (Minsan).